At a Higher Dose and Longer Duration, Ivermectin Still Not Effective Against COVID-19

Affiliations

Comment

Kirsten Bibbins-Domingo et al. JAMA. 2023.

. 2023 Mar 21;329(11):897-898.

doi: 10.1001/jama.2023.1922.

No abstract available

Comment in

The Ethics of Clinical Research: Managing Persistent Uncertainty.
London AJ, Seymour CW. London AJ, et al. JAMA. 2023 Mar 21;329(11):884-885. doi: 10.1001/jama.2023.1675. JAMA. 2023. PMID: 36806800 No abstract available.

The Ethics of Clinical Research: Managing Persistent Uncertainty.
London AJ, Seymour CW. London AJ, et al. JAMA. 2023 Mar 21;329(11):884-885. doi: 10.1001/jama.2023.1675. JAMA. 2023. PMID: 36806800 No abstract available.
Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial.
Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Slandzicki AJ, Lim SC, Cohen J, Kavtaradze D, Amon AP, Gabriel A, Gentile N, Felker GM, Jayaweera D, McCarthy MW, Sulkowski M, Rothman RL, Wilson S, DeLong A, Remaly A, Wilder R, Collins S, Dunsmore SE, Adam SJ, Thicklin F, Hanna GJ, Ginde AA, Castro M, McTigue K, Shenkman E, Hernandez AF; Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. Naggie S, et al. JAMA. 2023 Mar 21;329(11):888-897. doi: 10.1001/jama.2023.1650. JAMA. 2023. PMID: 36807465 Free PMC article.